Denali Therapeutics Inc

2026-03-04 09:52:14

Fisher Asset Management LLC significantly increased its stake in Denali Therapeutics Inc. by 7.6%, acquiring an additional 115,505 shares. This raised their total holdings to 1,631,496 shares, valued at $23.689 million, representing about 1.11% of the company. Despite insider stock sales in early January by CEO Ryan J. Watts and Alexander O. Schuth, analysts maintain a consensus "Moderate Buy" rating for Denali Therapeutics with an average price target of $32.45.

2026-03-03 17:52:14

Denali Therapeutics (DNLI) is under scrutiny after reporting wider losses and filing a new common stock shelf registration, which could lead to future share dilution. Despite a recent positive short-term stock performance, its valuation shows a Price to Book ratio of 3.3x, which is considered fair against its estimated value but slightly expensive compared to the broader US biotech industry. A Discounted Cash Flow (DCF) model suggests the current share price of $21.18 is below its estimated fair value of $32.80, indicating a potential discount for investors.

2026-03-02 22:51:31

Jefferies has reiterated a Buy rating and a $40 price target for Denali Therapeutics Inc. (NASDAQ:DNLI) due to positive regulatory developments in gene therapy for rare diseases. The firm places a high probability of success on Denali's Tivi/DNL310 treatment for Hunter syndrome, with a PDUFA date of April 5, 2026. Despite concerns raised by the FDA regarding a competing drug for Hunter syndrome, Jefferies believes these issues are program-specific and Denali's approach is favorable, potentially de-risking its broader ETV franchise.

2026-03-02 17:51:31

This article compiles a series of trade ideas and technical analyses for Denali Therapeutics Inc. (4DN/DNLI) from various traders and analysts. The analyses cover potential bullish and bearish movements, highlighting technical indicators like falling wedges, double bottoms, moving averages, and Aroon indicators, alongside significant company news regarding DNL151. Many contributors express a bullish outlook based on technical patterns and recent financial news, while some caution about resistance levels and market dynamics.

2026-03-02 12:52:40

BTIG Research has raised its price target for Denali Therapeutics (NASDAQ:DNLI) to $36.00 from $32.00, maintaining a "buy" rating and suggesting a nearly 70% potential upside. This adjustment comes amidst mixed analyst ratings, though the consensus remains a "Moderate Buy." The article also details recent insider stock sales by CEO Ryan J. Watts and Alexander O. Schuth, as well as institutional investor activity in the company.

2026-02-27 17:51:31

Denali Therapeutics (Nasdaq: DNLI) reported its Q4 and full-year 2025 financial results, alongside significant program updates. The company is preparing for the commercial launch of tividenofusp alfa for Hunter syndrome, with an FDA PDUFA date of April 5, 2026, and has made progress across its TransportVehicle platform programs. Denali also strengthened its financial position through a $275.0 million synthetic royalty deal with Royalty Pharma and a $200.0 million public offering, bringing its cash and marketable securities to approximately $966.2 million by the end of 2025.